Pieris Average Payables from 2010 to 2024

PIRS Stock  USD 11.72  0.12  1.03%   
Pieris Pharmaceuticals Average Payables yearly trend continues to be comparatively stable with very little volatility. Average Payables will likely drop to about 1.2 M in 2024. Average Payables is the average amount owed to suppliers and creditors over a specific period, reflecting Pieris Pharmaceuticals' payment cycle and credit terms with suppliers. View All Fundamentals
 
Average Payables  
First Reported
2010-12-31
Previous Quarter
2.2 M
Current Value
1.2 M
Quarterly Volatility
762.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pieris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pieris main balance sheet or income statement drivers, such as Interest Expense of 12.3 M, Selling General Administrative of 13.5 M or Other Operating Expenses of 46.1 M, as well as many exotic indicators such as Price To Sales Ratio of 0.36, Dividend Yield of 0.0 or PTB Ratio of 0.58. Pieris financial statements analysis is a perfect complement when working with Pieris Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Pieris Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Pieris Pharmaceuticals Technical models . Check out the analysis of Pieris Pharmaceuticals Correlation against competitors.
For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

Latest Pieris Pharmaceuticals' Average Payables Growth Pattern

Below is the plot of the Average Payables of Pieris Pharmaceuticals over the last few years. It is the average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers. Pieris Pharmaceuticals' Average Payables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pieris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Average Payables10 Years Trend
Slightly volatile
   Average Payables   
       Timeline  

Pieris Average Payables Regression Statistics

Arithmetic Mean1,642,158
Geometric Mean1,457,468
Coefficient Of Variation46.44
Mean Deviation703,577
Median1,722,360
Standard Deviation762,650
Sample Variance581.6B
Range1.7M
R-Value0.72
Mean Square Error297.8B
R-Squared0.52
Significance0
Slope123,503
Total Sum of Squares8.1T

Pieris Average Payables History

20241.2 M
20232.2 M
20172.4 M
20161.7 M
20151.2 M

About Pieris Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Pieris Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Pieris Pharmaceuticals investors use historical funamental indicators, such as Pieris Pharmaceuticals's Average Payables, to determine how well the company is positioned to perform in the future. Although Pieris Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Pieris Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pieris Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pieris Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pieris Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Average Payables2.2 M1.2 M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pieris Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Pieris Pharmaceuticals is a strong investment it is important to analyze Pieris Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pieris Pharmaceuticals' future performance. For an informed investment choice regarding Pieris Stock, refer to the following important reports:
Check out the analysis of Pieris Pharmaceuticals Correlation against competitors.
For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Pieris Stock analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stocks Directory
Find actively traded stocks across global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is Pieris Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pieris Pharmaceuticals. If investors know Pieris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pieris Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(21.60)
Revenue Per Share
38.026
Quarterly Revenue Growth
(0.78)
Return On Assets
(0.15)
Return On Equity
(0.90)
The market value of Pieris Pharmaceuticals is measured differently than its book value, which is the value of Pieris that is recorded on the company's balance sheet. Investors also form their own opinion of Pieris Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pieris Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pieris Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pieris Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pieris Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pieris Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pieris Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.